Regulating Cell and Gene Therapy Activity

Video

Paul Wotton, PhD, chief executive officer, Obsidian Therapeutics, discussed the company’s pipeline and technologies.

“We are focused on developing the next generation of both cell and gene therapies where the activity of those therapies can be regulated in the same way that you would regulate the use of a small molecule in a dose dependent manner in patients. And the advantage that gives us is that we can control these therapies now, like they've never been controlled before.”

Obsidian Therapeutics is targeting oncologic indications with cell and gene therapies developed with the use of their cytoDRIVE platform. Their lead program, cytoTIL15, is a tumor-infiltrating lymphocyte (TIL) therapy in investigational new drug (IND)-enabling studies for melanoma as well as preclinical studies for head and neck squamous cell carcinomas and discovery phases for other oncologic indications.

Obsidian presented data on cytoTIL15 at the European Society for Medical Oncology Congress, September 16-21, 2021. The presentation showcased cytoTIL15’s cytotoxic CD8+ T-cell phenotype and its anti-tumor cytotoxicity and polyfunctionality that offers it advantages over other TILs. The therapy also demonstrated favorable antigen-independent expansion and persistence.

GeneTherapyLive spoke with Paul Wotton, PhD, chief executive officer, Obsidian Therapeutics, to learn more about Obsidian’s programs and technologies. He also discussed partnerships the company has formed to collaborate on their cell and gene therapies in development.

REFERENCE
Obsidian Therapeutics to present preclinical data from cytoTIL15 program at the European Society for Medical Oncology Congress 2021. News release. Obsidian Therapeutics. September 15, 2021. https://obsidiantx.com/2021/09/15/obsidian-therapeutics-to-present-preclinical-data-from-cytotil15-program-at-the-european-society-for-medical-oncology-congress-2021/
Recent Videos
Ben Samelson-Jones, MD, PhD, assistant professor pediatric hematology, Perelman School of Medicine, University of Pennsylvania and Associate Director, Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Steven W. Pipe, MD, a professor of pediatric hematology/oncology at CS Mott Children’s Hospital
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
Related Content
© 2024 MJH Life Sciences

All rights reserved.